SubHero Banner

Tivicay® (dolutegravir), Tivicay PD (dolutegravir) – Expanded indication, New formulation approval

June 12, 2020 - The FDA announced the approval of ViiV Healthcare’s Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for suspension, in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg.

Download PDF